ClinicalTrials.Veeva

Menu
L

Louisiana Heart Center | Covington, LA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Semaglutide
Cholesterol
JK07
Droxidopa
EMPagliflozin
Ranolazine
Inclisiran
sodium

Parent organization

This site is a part of Louisiana Heart Center

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 8 total trials

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION)

V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous co...

Enrolling
Peripheral Endovascular Intervention
Percutaneous Coronary Intervention
Drug: Normal Saline (Placebo)
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular...

Active, not recruiting
Cardiovascular Disease
Drug: Cagrilintide
Drug: Semaglutide

This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in part...

Enrolling
Heart Failure With Preserved Ejection Fraction
Heart Failure With Reduced Ejection Fraction
Drug: JK07
Drug: Placebo

Trial sponsors

Novo Nordisk logo
Boehringer Ingelheim logo
Duke University logo
Gilead Sciences logo
Lundbeck logo
S

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems